Compare SVRE & SCNI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SVRE | SCNI |
|---|---|---|
| Founded | 2014 | 2003 |
| Country | Israel | Israel |
| Employees | 50 | N/A |
| Industry | | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.8M | 2.3M |
| IPO Year | N/A | 2014 |
| Metric | SVRE | SCNI |
|---|---|---|
| Price | $4.11 | $0.85 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 35.5K | ★ 7.8M |
| Earning Date | 05-08-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 50.00 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $1,793.31 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.55 | $0.45 |
| 52 Week High | $5.69 | $6.18 |
| Indicator | SVRE | SCNI |
|---|---|---|
| Relative Strength Index (RSI) | 55.30 | 62.90 |
| Support Level | $3.24 | $0.58 |
| Resistance Level | $4.98 | $0.94 |
| Average True Range (ATR) | 0.38 | 0.07 |
| MACD | 0.01 | 0.01 |
| Stochastic Oscillator | 39.03 | 54.52 |
Saverone 2014 Ltd is engaged in the design, development, and commercialization of transportation and safety solutions, designed to prevent car accidents based on its patented technology of detecting, analyzing, and locating cellular phone radio frequency, or RF signals. The company is developing two product lines: the first is an In-Cabin Driver Distraction Prevention Solution (known as SaverOne system), or DDPS; and the second is an Advanced Driver-Assistance System, or ADAS, product that detects vulnerable road users, or VRUs, and provides a warning to the vehicle regarding potential collision. Geographically, Saverone generates maximum revenue from Europe and the rest from Israel.
Scinai Immunotherapeutics Ltd is a biopharmaceutical company with two complementary business units, one focused on in-house development of inflammation and immunology (I&I) biological therapeutic products beginning with a pipeline of nanosized VHH antibodies (NanoAbs) targeting diseases with large unmet medical needs, and the other a boutique CDMO providing services to help biotech companies efficiently bring their products to market by leveraging Scinai's drug development and GMP and non-GMP manufacturing capabilities for pre-clinical and clinical studies. The company generates maximum revenue from the provision of CDMO (Contract Development and Manufacturing Organization) services.